The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Skin, hair & anti-aging

Minoxidil (oral)

Low-dose oral minoxidil for hair loss - originally a blood pressure drug.

1 min read 10 sources

To the product To the sources
Still from the explainer video about this entry
Compound approved · since 1979Lab tested in the shop

No time to read it all? The video sums up the whole entry in about a minute, from how it works to the studies and storage.

Summary

At a glance

Sources checked on 26 Oct 2026

In the largest safety analysis
1,404 patients

Low dose for hair loss, only 1.7% stopped because of side effects4

Increased body hair
15.1 %

Most common side effect in the same analysis, 0.5% stopped because of it4

Response after 6 months
63.4 %

41 patients with pattern hair loss, men 73.1%, women 40.0%5

In the review
17 studies

With 634 patients in total, most often pattern hair loss2

Phase 3 in the registry
2 trials

Minoxidil as a tablet, 1 of them completed, as of 26 Oct 20269

  • Minoxidil was developed as a tablet for high blood pressure. As a side effect hair grew more, which turned it into a hair loss drug.710
  • The active form is minoxidil sulfate. It opens ATP-sensitive potassium channels, shortens the resting phase of the hair and extends the growth phase.78
  • A review found 17 studies with 634 patients, a randomised trial in men did not see the tablet clearly ahead of the solution applied to the scalp.23
  • Most often body hair grows more as well. Dizziness, fluid retention and a racing heart were rare in an analysis of 1,404 patients.4
  • How well it works apparently depends on the enzyme in the hair follicle that activates minoxidil. Everything here is the state of research, not a recommendation.5
Profile

Updated June 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~4 hours

Half-life ~4 hours
After 8 hours: 25 %
Hour 4 · 50 %Hour 8 · 25 %Hour 12 · 12.5 %Hour 20 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
Vasodilator

oral, low-dose

Use
Oral

1x per day

Half-life
about 4 hours
Status
Prescription

off-label for hair loss

Sizes
2.5 to 10 mg

3 sizes in the shop

Contents 13 sections
  1. At a glance
  2. What is oral minoxidil?
  3. How it works
  4. Use and dosing
  5. What the research shows
  6. Research status
  7. On the skin
  8. Side effects
  9. Storage
  10. Related compounds
  11. FAQ
  12. Glossary
  13. Sources

What is oral minoxidil?

Minoxidil was originally a blood pressure drug whose most striking side effect - increased hair growth - turned it into a hair loss treatment. Taken orally at low dose it is a convenient alternative to the topical solution, since daily application is no longer needed.

This information is for research and educational purposes only. No medical advice.

Comparison

Three approaches to pattern hair loss

Where the tablets for pattern hair loss act, as stated in the TPD lexicon. Tap a card to open its entry.

Potassium channel opener Minoxidil (oral) KATP
5-alpha reductase inhibitor type 2 Finasteride SRD5A2 5-alpha reductase inhibitor types 1 and 2 Dutasteride SRD5A1SRD5A2

Minoxidil promotes growth at the follicle, the other two slow down the formation of DHT. SRD5A1 and SRD5A2 are the two forms of 5-alpha reductase. 710

How it works

Minoxidil widens blood vessels and improves blood flow to the hair follicles, supports the energy supply of follicle cells and prolongs the growth phase (anagen) of the hair. The exact mechanism is not fully understood, but the effect is well documented.

Where it acts

One receptor, several organs

Tap a point or a card. Colour = receptor, grey = effect seen in trials.

  1. Hair follicle

    Resting phase shorter, growth phase longer, follicles larger7

    KATP
  2. Blood vessels

    Vessel muscles relax, blood pressure falls7

    KATP
  3. Heart

    Racing heart in 0.9% of patients4

    Observed in trials

Targets in the ChEMBL database10

Compound CHEMBL802: one recorded mechanism, Opener, as minoxidil sulfate.

ATP-sensitive potassium channel (SUR2 with Kir6.2)
Gene
ABCC9, KCNJ11
UniProt
O60706, Q14654
ChEMBL
CHEMBL2095198
Action
Opener, as minoxidil sulfate
Glass hair follicle with a growing hair, surrounded by fine glass vessels, with blue molecules beside the root
Minoxidil acts on the follicle and on the vessels. Symbolic image.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
White box with the TPD logo, next to a blister with ten round white tablets and two loose tablets on a bright lab bench
Tablets in a blister, once a day. Symbolic image.

What the research shows

The review by Randolph & Tosti (J Am Acad Dermatol, 2021) summarizes the data on low-dose oral minoxidil: effective in androgenetic alopecia and other hair loss types, with a good safety profile at low dose.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Clinical improvement after 6 months5

41 patients with pattern hair loss, share with improvement

All5
Minoxidil as a tablet 63.4%
Men5 19 of 26
Minoxidil as a tablet 73.1%
Women5 6 of 15
Minoxidil as a tablet 40.0%
Low enzyme activity in the follicle5
Minoxidil as a tablet 85.0%
High enzyme activity in the follicle5
Minoxidil as a tablet 43.0%

Sulfotransferase was measured in plucked hairs, the enzyme that activates minoxidil. Small study without a control group.

Less shedding in chronic telogen effluvium6

36 women, shedding score at baseline 5.64 on average

After 6 months6
Minoxidil as a tablet -1.70 Punkte
After 12 months6
Minoxidil as a tablet -2.58 Punkte

Retrospective analysis without placebo. All 36 women stayed on for 12 months, 13 developed more facial hair.

Terminal hair density after 24 weeks3

Double-blind trial, 68 men analysed, difference in gain in hairs per cm²

Frontal scalp3
Lead of the tablet over the solution +3.1 Haare/cm²
Vertex3
Lead of the tablet over the solution +23.4 Haare/cm²

Neither difference was statistically significant. In the photo assessment the tablet was ahead only at the vertex. So the tablet was not superior to the solution.

From above: comb, petri dishes and a glass pipette around a frosted glass hair follicle sculpture with a few fresh hairs
Symbolic image.

Research status

Where the research stands

Minoxidil is approved as a tablet for high blood pressure. Shown are the registry trials in which minoxidil is swallowed or placed under the tongue, without pure solutions and foams. As of 26 Oct 2026. 9

  1. Preclinical Potassium channels in human hair follicles, organ culture
  2. Phase 1 4 trials, 2 completed
  3. Phase 2 2 trials, 1 completed
  4. Phase 3 2 trials, 1 completed
  5. Approval since 1979
142 participants in phase 3 Planned figures for running trials Approved: ChEMBL lists minoxidil with phase 4 as the highest phase and first approval in 1979. For hair loss the tablet is used off-label.10
Show all 4 phase 2 and 3 trials on a timelineHide timeline 2 completed 2 running 0 with results
Phase 2
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 4 trials on safety and pharmacokinetics, not shown as bars.

On the skin

Minoxidil also comes as a solution or foam applied to the scalp, which is the older and better studied form. In a large randomised study with 393 men the higher-concentration solution grew clearly more hair over 48 weeks than the lower-concentration one or placebo. Itching and scalp irritation were more common with it (Olsen 2002).

Hand touching a swirl of white cream on a light marble slab with water droplets and white flowers
Symbolic image.

Side effects

  • Systemic hypertrichosis (increased body hair) - the most common side effect.
  • Drop in blood pressure, faster pulse, occasional fluid retention.
  • Headache, rarely ankle edema.
  • Caution with pre-existing cardiovascular conditions.

Tolerability

Frequency of side effects

Out of 100 patients, how many had the side effect. A small trial in men and a large analysis without a control group.

49 of 100 Trial with 45 men, 24 weeks
15 of 100 Analysis of 1,404 patients
Event Trial with 45 men, 24 weeksAnalysis of 1,404 patients
Increased body hair4 49%15%
Headache4 14%0%
Lightheadedness4 0%2%
Fluid retention4 0%1%
Racing heart4 0%1%

In the small trial hair growth and headache come from the abstract (22 and 6 of 45 men). The large analysis counted 2,469 treatment periods, 1.7 percent stopped because of side effects, none were life-threatening.34

Storage

Store dry and cool, protected from light. Out of reach of children.

Three white tablet bottles of different sizes and a folded light blue towel on a white shelf
Dry, cool and protected from light. Symbolic image.
Level · Minoxidil (oral)

How the level builds up

One dose per day: each dose adds to what is left of the previous one.

Lexicon: Oral, 1x per day
Peak 1.02×Trough 0.02×
Day 1 · 2. dose
1.02× of the first dose
Plateau
from Day 0

98 % of the plateau after dose 1

Peak
1.02×

of the first dose

Trough
0.02×

before the next dose

Simplified model, values relative to the first dose, no dosing information. Dashed: the first dose alone, green: the plateau.

Related

Related compounds

A different path: all in the TPD lexicon.

Minoxidil (oral)
Finasteride Different path: slows DHT, tablet Dutasteride Different path: slows DHT via both enzyme forms Healthy Hair Skin Nails Blend Injectable blend for hair, skin and nails GHK-Cu Copper peptide from skin research

FAQ

Common questions about Minoxidil (oral)

Short answers, each backed by the sources below.

How does minoxidil act on hair?

It is not fully understood. In animal models minoxidil shortens the resting phase, resting follicles switch to growth earlier, the growth phase gets longer and the follicle larger. The active form is the sulfate, which opens potassium channels. Such channels were found in the dermal papilla of human hair follicles. In culture minoxidil and a channel blocker cancelled each other out.78

Is minoxidil approved as a tablet?

The compound is: ChEMBL lists minoxidil with phase 4 as the highest phase and first approval in 1979. As a tablet it lowers blood pressure via the vessels. For hair loss the low-dose tablet is used off-label. A phase 3 trial in women is running on the registry, one with tablets under the tongue in men has been completed.1079

Is the tablet better than the solution applied to the scalp?

In a double-blind trial with 90 men (68 analysed) the tablet was not superior after 24 weeks. The gain in hair density was somewhat higher at the vertex, but not statistically significant. Only the photo assessment put the tablet ahead at the vertex. Its advantage is more about daily life: no daily application. The solution itself is well studied: in a trial with 393 men the higher-concentration solution grew clearly more hair over 48 weeks than the lower-concentration one or placebo.31

Why does it not work equally for everyone?

Minoxidil is activated in the hair follicle by the enzyme sulfotransferase. In a study with 41 patients hair loss improved in 63.4 percent after 6 months, more often in men than in women. Surprisingly, patients with low enzyme activity responded better (85 against 43 percent). The authors see this as a way to estimate beforehand who benefits.5

Which side effects were seen?

In the largest analysis with 1,404 patients increased body hair was most common (15.1 percent). Lightheadedness (1.7), fluid retention (1.3), racing heart (0.9), headache (0.4), swelling around the eyes (0.3) and sleep problems (0.2 percent) were rare, 1.7 percent stopped. In a small trial in men almost half had more body hair.43

Does it also help with diffuse shedding?

In chronic telogen effluvium, long-lasting diffuse shedding without bald patches, it was studied in 36 women. The shedding score fell from 5.64 by 1.7 points after 6 months and by 2.58 points after 12 months. Blood pressure barely changed, 13 women developed more facial hair. It was a retrospective analysis without placebo.6

How good is the overall evidence?

A review found 17 studies with 634 patients in total up to April 2020, mostly on pattern hair loss, plus other forms. It rates the tablet as effective and well tolerated for healthy people who struggle with the solution. According to the authors larger randomised trials comparing doses are still missing.2

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Anagen
The growth phase of the hair. The longer it lasts, the longer and thicker the hair gets.
ATP-sensitive potassium channel
A channel in the cell membrane. When open it relaxes vessel muscles, in the hair follicle it is linked to growth.
Hypertrichosis
Increased hair growth on the body or face.
Minoxidil sulfate
The active form. It is made from minoxidil in the body and in the hair follicle.
Off-label
Use of an approved compound for a purpose it is not approved for.
Pattern hair loss
Androgenetic alopecia: hair loss due to genetic disposition and the effect of DHT on the follicle.
Sulfotransferase
Enzyme that converts minoxidil into its active form. Its activity in the follicle differs from person to person.
Telogen
The resting phase of the hair, at the end of which it falls out.
Telogen effluvium
Diffuse shedding because many hairs enter the resting phase at the same time.
Vasodilator
A compound that widens the blood vessels and so lowers blood pressure.

Evidence

Sources

Show all 10 sourcesHide sources 8 Studies1 Trial registry1 Database checked 26 Oct 2026

Studies

  1. Topical minoxidil solution: higher versus lower concentration and placebo

    Olsen et al., Journal of the American Academy of Dermatology, 2002

    DOI 10.1067/mjd.2002.124088 PMID 12196747
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Review of efficacy and safety of the tablet for hair loss

    Randolph and Tosti, Journal of the American Academy of Dermatology, 2021

    DOI 10.1016/j.jaad.2020.06.1009 PMID 32622136
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Tablet against solution in men, randomised

    Penha et al., JAMA Dermatology, 2024

    DOI 10.1001/jamadermatol.2024.0284 PMID 38598226
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Safety in 1,404 patients, several centres

    Vañó-Galván et al., Journal of the American Academy of Dermatology, 2021

    DOI 10.1016/j.jaad.2021.02.054 PMID 33639244
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Enzyme activity in the follicle and response

    Jimenez-Cauhe et al., Journal of Cosmetic Dermatology, 2024

    DOI 10.1111/jocd.16473 PMID 39034734
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Chronic telogen effluvium in women, retrospective

    Perera and Sinclair, F1000Research, 2017

    DOI 10.12688/f1000research.11775.1 PMID 29167734
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Review of the mechanism of action on hair

    Messenger and Rundegren, British Journal of Dermatology, 2004

    DOI 10.1111/j.1365-2133.2004.05785.x PMID 14996087
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  8. Potassium channels in human hair follicles

    Shorter et al., FASEB Journal, 2008

    DOI 10.1096/fj.07-099424 PMID 18258787
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials with oral minoxidil on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Mechanism and approval in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL802)

    Checked 26 Oct 2026 via ChEMBL

In the shop

Minoxidil (oral) in the catalog

Sizes, prices and shipping times are on the product page.

To the product